Abstract
We assessed the duration of the anti-cholecystokinin (CCK) action of FK480, a new non-peptide CCK-A receptor antagonist developed in Japan, in an in vivo study in rats, comparing it with CR 1505. Pancreatic exocrine secretion stimulated by intravenous infusion of CCK-8 (0.06 μg/kg per h) was measured at intervals of 0–24 h after the oral administration of FK480 (1.5 mg/kg) and CR 1505 (30 mg/kg). FK480 significantly inhibited both CCK-stimulated pancreatic juice volume flow and amylase output 0, 4, 8, and 12h after oral administration, whereas the inhibitory effect of CR 1505 had completely disappeared by 8h after oral administration. It was concluded that orally administered FK480 has a prolonged anti-CCK action.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Niederau C, Niederau M, Williams JA, et al. New proglumideanalogue CCK receptor antagonists: Very potent and selective for peripheral tissues. Am J Physiol 1986;251:G856-G860.
Makovec F, Bani M, Cereda R, et al. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneim Forsch Drug Res 1987;37:1265–1268.
Hosotani R, Chowdhury P, McKay D, et al. Effect of L364718, a new CCK antagonist, on amylase secretion in isolated rat pancreatic acini. Pancreas 1988;3:95–98.
Setnikar I, Bani M, Cereda R, et al. Anticholecystokinin activities of loxiglumide. Arzneim Forsch Drug Res 1987;7:1168–1171.
Louie DS, Liang JP, Owyang C. Characterization of a new CCK antagonist, L364, 718: In vitro and in vivo studies. Am J Physiol 1988;255:G261-G266.
Konturek SJ, Tasler J, Cieszkowski M, et al. Effect of cholecystokinin receptor antagonist on pancreatic responses to exogenous gastrin and cholecystokinin and to meal stimuli. Gastroenterology 1988;94:1014–1023.
Niederau M, Niederau C, Strohmeyer G, et al. Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo. Am J Physiol 1989;256:G150-G157.
Shiratori K, Shimizu K, Watanabe S, et al. Effect of CCK antagonists CR 1409 and CR 1505 on rat pancreatic exocrine secretion in vivo. Pancreas 1989;4:744–750.
Schwarzendrube J, Niederau M, Lüthen R, et al. Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers. Gastroenterology 1991;100:1683–1690.
Moriyoshi Y, Shiratori K, Takeuchi T, et al. A new CCK-A antagonist, KSG-504, administered intraduodenally, inhibits pancreatic secretion in rats. Pancreas 1994;9:225–229.
Takàcs T, Pap À. Perspectives of CCK antagonists in pancreatic research. Part II. Experimental studies. Int J Pancreatol 1991; 10:1–8.
Rovati LC. Perspectives of CCK antagonists in pancreatic research and clinical use. Part I Int J Pancreatol 1991;8:215–226.
Moriyoshi Y, Shiratori K, Takeuchi T, et al. Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats. Pancreas 1995;10: 295–300.
Setnikar I, Chisté R, Makovec F, et al. Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. Arzneim Forsch Drug Res 1988;38:716–720.
Winer BJ. Statistical priciples in experimental design. 2nd Ed. New York: McGraw Hill, 1971;149–260.
Ito H, Sogabe H, Nakarai T, et al. FK480: a novel CCK-A receptor antagonist (abstract). Jpn J Pharmacol 1992;58(Suppl I):130P.
Akiyama T, Otsuki M. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini. Pancreas 1994;9:324–331.
Lotti VJ, Pendleton RG, Gould RJ, et al. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 1987;241:103–109.
Corazziari E, Ricci R, Biliotti D, et al. Oral administration of loxiglumide (CCK antagonist) inhibits postprandial gallbladder contraction without affecting gastric emptying. Dig Dis Sci 1990; 35:50–54.
Watanabe N, Otsuki M. Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on ceruleinstimulated pancreatic exocrine seeretion. Int J Panereatol 1993; 13:129–137.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moriyoshi, Y., Shiratori, K., Iwabe, C. et al. Duration of anti-cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK 480 administered orally. J Gastroenterol 31, 249–253 (1996). https://doi.org/10.1007/BF02389525
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02389525